Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 6 for:    mvx

Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02999646
Recruitment Status : Active, not recruiting
First Posted : December 21, 2016
Last Update Posted : January 13, 2021
Sponsor:
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research

Brief Summary:
The purpose of this trial is to determine the efficacy of the immunotherapy with MVX-ONCO-1 in patients with advanced head and neck squamous cell carcinoma. MVX-ONCO-1 consists of dead tumor cells from the patient itself and genetically modified cells within a capsule. The whole treatment takes 9 weeks. At weeks 1, 2, 3, 4, 6 and 8, the tumor cells are injected underneath the skin and two capsules are implanted for a week. At weeks 2, 3, 4, 5, 7 and 9 the capsules are removed again. The patients are then followed-up for 5 years.

Condition or disease Intervention/treatment Phase
Head and Neck Squamous Cell Carcinoma Other: MVX-ONCO-1 Not Applicable

Detailed Description:

Patients with advanced HNSCC after platinum-based palliative chemotherapy have a poor prognosis, with no well-defined standard treatment and a survival between 6 to 9 months.

MVX-ONCO-1 is a patient specific, cell-based, active immunotherapy, where the patient's immune response to tumor cells is stimulated and/or increased by triggering an immune response against the patients' cancer cells.

Rationale for this trial is:

  1. HNSCC: there is a clear medical need in this patient population,
  2. Relapsing HNSCC often have accessible tumor tissue,
  3. HNSCC is considered an immunogenic tumor.

This phase II study is a first step towards a potentially innovative immunotherapy for HNSCC.

MVX-ONCO-1 is composed of:

  1. An immune-modulator (GM-CSF: granulocyte-macrophage colony stimulating factor) released from an immuno-protected, encapsulated, allogeneic, genetically modified cell line (MVX-1), and
  2. Irradiated, autologous tumor cells as source of antigen.

Each treatment consists of two macrocapsules containing the MVX-1 cell line implanted subcutaneously and lethally irradiated autologous tumor cells injected subcutaneously. Eligible patients will receive a treatment once weekly starting on week 1 for 4 weeks followed by two additional treatments 2 weeks apart (total 6 treatments over 8 weeks). Each pair of macrocapsules is removed after 1 week, and the last implanted capsules are removed in week 9. The patients are then followed-up for 5 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 41 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: antitumor immunization MVX-ONCO-1
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced Head and Neck Squamous Cell Carcinoma. A Single Arm, Open Label, Multicenter Phase II Trial.
Actual Study Start Date : July 25, 2018
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2027

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: MVX-ONCO-1
MVX-ONCO-1 vaccine treatment once weekly starting on week 1 for 4 weeks followed by two additional treatments 2 weeks apart (total 6 treatments over 8 weeks). Each treatment consists of two macrocapsules containing the MVX-1 cell line and lethally irradiated autologous tumor cells.
Other: MVX-ONCO-1
Autologous cells: 1 vial containing 4x10^6 irradiated tumor cells Capsules: 2 biocompatible capsules loaded with 8x10^5 MVX-1 cells




Primary Outcome Measures :
  1. Overall Survival at 26 weeks (OS) [ Time Frame: at 26 weeks from registration ]
    The primary endpoint of the trial is Overall Survival (OS) at 26 weeks defined as percentage of patients alive 26 weeks from registration. Patients who are lost to follow-up with a date they were last known to be alive less than 26 weeks after registration will be counted as failures for this endpoint.


Secondary Outcome Measures :
  1. Time to subsequent therapy (TST) [ Time Frame: assessed within 5 years ]
    defined as time from registration until documented start of subsequent therapy. Patients who did not start a subsequent therapy will be censored at the last date they were known to be alive

  2. Duration of response (DOR) [ Time Frame: assessed within 5 years ]
    defined as time from the date when a patient first meets the criteria for complete response (CR) or partial response (PR) until documented radiologic progression, relapse, or death due to disease progression, whichever occurs first. Patients not having an event at the time of analysis and patients starting a new anticancer therapy in the absence of an event will be censored at the date of their last tumor assessment showing non-progression before starting a new treatment. DOR will only be analyzed in the subgroup of patients achieving CR or PR during trial treatment based on RECIST 1.1.

  3. Objective response rate (ORR) [ Time Frame: at 6, 13, 26, 39 and 52 weeks ]

    defined as the proportion of patients having CR or PR at the respective time point after registration plus/minus 1 week at week 6, 13, 26, and plus/minus 2 weeks at week 39 and 52 after registration.

    The response rate will be analyzed based on RECIST 1.1. CR and PR will only be counted if the response is confirmed at least 4 weeks later


  4. Disease control rate (DCR) [ Time Frame: at 6, 13, 26, 39 and 52 weeks ]
    defined as the proportion of patients having CR, PR, or stable disease (SD) at the respective time point after registration plus/minus 1 week at week 6, 13, 26, and plus/minus 2 weeks at week 39 and 52 after registration. The disease control rate will be analyzed based on RECIST 1.1. CR and PR will only be counted if the response is confirmed at least 4 weeks later.

  5. Best overall response [ Time Frame: assessed within 5 years ]
    defined as best response achieved at any time during or after the trial treatment before starting a new anticancer treatment. Best overall response will be analyzed based on RECIST 1.1. CR and PR will only be counted if the response is confirmed at least 4 weeks later.

  6. Objective response according to iRECIST (iOR) [ Time Frame: at 6, 13, 26, 39 and 52 weeks ]
    defined as any complete response (CR/iCR) or partial response (PR/iPR) according to RECIST1.1 or iRECIST criteria achieved before new anti-cancer treatment is given. Any patient with CR/iCR or PR/iPR as best observed response under trial treatment will be considered as a success; otherwise they will be considered as a failure. Patients without any tumor assessment or with non-evaluable response (NE) under trial treatment will be considered as failures for this endpoint.

  7. Progression Free Survival (PFS) [ Time Frame: assessed within 5 years ]
    defined as the time from registration until progression according to RECIST 1.1 or death from any cause, whichever occurs first. Patients not having an event at the time of analysis and patients starting a new anticancer therapy in the absence of an event will be censored at the date of their last tumor assessment showing non-progression before starting a new treatment.

  8. Progression-free survival according to iRECIST (iPFS) [ Time Frame: assessed within 5 years ]
    defined as the time from registration until disease progression according to iRECIST criteria (iPD) or death due to any reason, whichever occurs first.

  9. PFS at 6, 13, 26, 39, and 52 weeks [ Time Frame: at 6, 13, 26, 39, and 52 weeks ]
    will be estimated using the Kaplan-Meier estimator for PFS at the respective time point after registration plus/minus 1 week at week 6, 13, 26, and plus/minus 2 weeks at week 39 and 52 after registration.

  10. OS [ Time Frame: assessed within 5 years ]
    defined as time from registration until death from any cause. Patients which are still alive will be censored at the date they were last known to be alive.

  11. PFS under the first subsequent treatment [ Time Frame: assessed within 5 years ]
    defined as the time from start of the first subsequence treatment until progression according to RECIST 1.1 or death from any cause, whichever occurs first. Patients not having an event at the time of analysis and patients starting next line of anticancer therapy in the absence of an event will be censored at the date of their last tumor assessment showing non-progression before starting new treatment.

  12. Adverse and serious adverse events [ Time Frame: assessed within 5 years ]
    All adverse events (AE) will be assessed according to NCI CTCAE v4.0



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria for pre-registration:

  • Written informed consent according to ICH/GCP regulations before pre-registration
  • Histologically confirmed diagnosis of head and neck squamous carcinoma (oral cavity, pharynx, larynx), Stage III/IV in recurrent or metastatic stage. Patients with local relapse for whom a curative treatment is available cannot be enrolled. Furthermore, all patients should have no other therapeutic option left.
  • One line of prior anticancer therapy for recurrent or metastatic disease. Patients with locally advanced disease experiencing local relapse within 6 months of last dose of curative intended, platinum-based chemo-radiation with or without prior surgery can also be included.
  • Primary tumor and/or metastasis amenable for partial/total surgery or tap
  • Measurable or evaluable disease according to RECIST 1.1 criteria
  • Patients age ≥ 18 years
  • WHO performance status 0-2
  • Adequate hematological values: neutrophils ≥1x10^9/L, platelets ≥70x10^9/L
  • Adequate hepatic function: bilirubin ≤2 x ULN; AST and ALT and AP ≤2.5 x ULN (except for patients with liver metastasis: ≤5 x ULN)
  • Adequate renal function (creatinine clearance >40mL/min/1.73m^2, calculated according to the corrected formula of Cockcroft-Gault
  • Foreign protein DTH test positive to at least one antigen
  • Women with child-bearing potential are using effective contraception, are not pregnant and agree not to become pregnant after pre-registration, during trial treatment and during the 6 months thereafter. A negative blood pregnancy test before inclusion into the trial is required for all women with child-bearing potential
  • Men agree not to father a child during trial treatment and during 6 months thereafter

Exclusion Criteria for pre-registration:

  • Known or suspected CNS metastases or active leptomeningeal disease
  • History of hematologic or primary solid tumor malignancy, unless in remission for at least 3 years from registration with the exception of T1-2 prostate cancer Gleason score <6 (PSA<10 ng/mL), adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer
  • Participated in any other investigational study or received an experimental therapeutic procedure considered to interfere with the study in the 4 preceding weeks of the pre-registration
  • Any chemotherapy treatment in the 4 preceding weeks of the pre-registration
  • Concomitant use of other anti-cancer drugs
  • Planned radiotherapy (other than symptom control)
  • Severe or uncontrolled cardiovascular disease uncontrolled hypertension (sustained systolic blood pressure > 150 mm Hg and/or diastolic > 100 mm Hg despite antihypertensive therapy)
  • History of cerebrovascular accident or intracranial hemorrhage within 6 months prior to pre-registration
  • Positive HIV test
  • Known history of HTLV-1, HTLV-2, or active chronic Hepatitis C or Hepatitis B Virus infection or any uncontrolled active systemic infection requiring intravenous (iv) antimicrobial treatment
  • Known severe allergy to reagents in the study product (MVX-ONCO-1) such as penicillin, streptomycin
  • Systemic disease other than cancer that is not controlled by approved medication
  • Patient with active autoimmune disease
  • Chronic immunosuppressive treatment exceeding 20 mg/day of prednisone or an equivalent corticosteroid. Note: In acute situations prednison exceeding 20mg/day or equivalent(day is allowed during 7 days)
  • Women who are pregnant or breast feeding
  • Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications

Inclusion criteria for registration:

  • Primary tumor and/or metastasis amenable for partial/total surgery or tap and subsequent cell harvest > 26x10^6 cells
  • Measurable or evaluable disease according to RECIST 1.1 criteria
  • WHO performance status 0-2
  • Baseline QoL forms have been completed
  • Adequate hematological values: neutrophils ≥1x10^9/L, platelets ≥70x10^9/L
  • Adequate hepatic function: bilirubin ≤2 x ULN; AST and ALT and AP ≤ 2.5 x ULN (except for patients with liver metastasis: ≤5 x ULN)
  • Adequate renal function (creatinine clearance >40 mL/min/1.73m^2, calculated according to the corrected formula of Cockcroft-Gault
  • Women with child-bearing potential are using effective contraception, are not pregnant or lactating and agree not to become pregnant after registration, during trial treatment, and during the 6 months thereafter. A negative blood pregnancy

Exclusion criteria for registration:

  • Known or suspected CNS metastases or active leptomeningeal disease
  • Concomitant use of other anti-cancer drugs
  • Planned radiotherapy (other than symptom control)
  • Systemic disease other than cancer, that is not controlled by approved medication
  • Chronic immunosuppressive treatment exceeding 20 mg/day of prednisone or an equivalent corticosteroid. Note: In acute situations prednisone exceeding 20 mg/day or equivalent is allowed during 7 days
  • Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications
  • Women who are pregnant or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02999646


Locations
Layout table for location information
Switzerland
Inselspital Bern
Bern, Switzerland, 3010
HUG Hôpitaux Universitaires Genève
Geneva, Switzerland, 1211
Centre Hospitalier Universitaire Vaudois CHUV
Lausanne, Switzerland, CH-1011
Kantonsspital St. Gallen
St. Gallen, Switzerland, CH-9007
Universitätsspital Zürich
Zürich, Switzerland, 8091
Sponsors and Collaborators
Swiss Group for Clinical Cancer Research
Investigators
Layout table for investigator information
Study Chair: Olivier Michielin, Prof CHUV Lausanne
Layout table for additonal information
Responsible Party: Swiss Group for Clinical Cancer Research
ClinicalTrials.gov Identifier: NCT02999646    
Other Study ID Numbers: SAKK 11/16
First Posted: December 21, 2016    Key Record Dates
Last Update Posted: January 13, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Swiss Group for Clinical Cancer Research:
head and neck squamous cell carcinoma
cancer
HNSCC
immunotherapy
MVX-ONCO-1
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Squamous Cell
Squamous Cell Carcinoma of Head and Neck
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Head and Neck Neoplasms
Neoplasms by Site